Molecular changes in pancreatic cancer: Implications for molecular targeting therapy

Acta Gastro-Enterologica Belgica

Volumn 75, Issue 2, 2012, Pages 210-214

  Demetter, P ^a   Marechal R ^a   Verset, L ^a   Salmon, I ^a   Bachet, J B ^b   van Laethem, J L ^a  

^a ERASME HOSPITAL   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adenocarcinoma; Chemokines; Gemcitabine; Nucleoside transporters; Pancreas; Stellate cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; CURCUMIN; DEOXYCYTIDINE KINASE; EPIDERMAL GROWTH FACTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEMCITABINE; GEMCITABINE ELAIDATE; PLATELET DERIVED GROWTH FACTOR; SMAD7 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRAPIDIL; VASCULOTROPIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMOKINE CXCL12; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; RECEPTORS, CXCR4;

EID: 84863556286     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. ALEXAKIS N., HALLORAN C., RARATY M., GHANEH P., SUTTON R., NEOPTOLEMOS JP. Current standards of surgery for pancreatic cancer. Br. J. Surg., 2004, 91: 1410-1427.
2. JEMAL A., SIEGEL R., WARD E., MURRAY T., XU J., THUN M.J. Cancer statistics. CA Cancer J. Clin., 2007, 57: 43-66.
3. Cancer incidence in Belgium, 2008, Belgian Cancer Registry, Brussels 2011.
4. COLEMAN M.P., GATTA G., VERDECCHIA A., ESTEVE J., SANT M., STORM H. et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann. Oncol., 2003; 14 Suppl 5: V128-V149.
5. NIETO J., GROSSBARD M.L., KOZUCH P. Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist, 2008, 13: 562-576.
6. OETTLE H., POST S., NEUHAUS P., GELLERT K., LANGREHR J., RIDWELSKI K. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 2008, 297: 267-277.
7. NEOPTOLEMOS J.P., STOCKEN D.D., FRIESS H., BASSI C., DUNN J.A., HICKEY H. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med., 2004, 350: 1200-1210.
8. UENO H., KOSUGE T., MATSUYAMA Y., YAMAMOTO J., NAKAO A., EGAWA S. et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br. J. Cancer, 2009, 101: 908-915.
9. BURRIS H.A. 3RD., MOORE M.J., ANDERSEN J., GREEN M.R., ROTHENBERG M.L., MODIANO M.R. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15: 2403-2413.
10. NEOPTOLEMOS J.P., STOCKEN D.D., BASSI C., GHANEH P., CUNNINGHAM D., GOLDSTEIN D. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine for pancreatic cancer: a randomized controlled trial. JAMA 2010, 304: 1073-1081.
11. VAN LAETHEM J.L., HAMMEL P., MORNEX F., AZRIA D., VAN TIENHOVEN G., VERGAUWE P. et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a ramdomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J. Clin. Oncol., 2010, 28: 4450-4456.
12. BERGMAN A.M., PINEDO H.M., PETERS G.J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updates, 2002, 5: 19-33.
13. HUANG P., CHUBB S., HERTEL L.W., GRINDEY G.B., PLUNKETT W. Action of 2'2'-difluorodeoxycytidine on DNA synthesis. Cancer Res., 1991, 51: 6110-6117.
14. RUIZ VAN HAPEREN V.W.T., VEERMAN G., VERMORKEN J.B., PETERS G.J. 2'2'-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA from tumor cell lines. Biochem. Pharmacol., 1993, 46: 762-766.
15. SPRATLIN J., SANGHA R., GLUBRECHT D., DABBAGH L., YOUNG D., DUMONTET C. et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabinetreated pancreas adenocarcinoma. Clin. Cancer Res., 2004, 10: 6956-6961.
16. FARRELL J.J., ELSALEH H., GARCIA M., LAI R., AMMAR A., REGINE W.F. et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology, 2009, 136: 187-195.
17. MARECHAL R., MACKEY JR., LAI R., DEMETTER P., PEETERS M., POLUS M. et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res., 2009, 15: 2913-2919.
18. AKITA H., ZHENG Z., TAKEDA Y., KIM C., KITTAKA N., KOBAYASHI S. et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene, 2009, 28: 2903-2909.
19. KURATA N., FUJITA H., OHUCHIDA K., MIZUMOTO K., MAHAWITHITWONG P., SAKAI H. et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int. J. Oncol., 2011, 39: 473-482.
20. RAUCHWERGER D.R., FIRBY P.S., HEDLEY D.W., MOORE M.J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res., 2000, 60: 6075-6079.
21. TSUJIE M., NAKAMORI S., NAKAHIRA S., TAKEDA S., TAKAHASHI Y., HAYASHI N. et al. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas, 2006, 33: 142-147.
22. GIOVANNETTI E., MEY V., NANNIZZI S., PASQUALETTI G., DEL TACCA M., DANESI R. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther., 2006, 5: 1387-1395.
23. BERGMAN A.M., FICHTNER I., BALZARINI J., FODSTAD O., KUIPER C.M., BREISTOL K. et al. Oral antitumor effect and in vitro antiproliferative activity of CP-4126, a fatty acid derivative of gemcitabine in cell lines and human cancer xenograft models. Proc. Am. Assoc. Cancer Res., 2005, 46: 1444.
24. BERGMAN A.M., ADEMA A.D., BALZARINI J., BRUHEIM S., FICHTNER I., NOORDHUIS P. et al. Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest. New Drugs, 2011, 23: 456-466.
25. MARECHAL R., MACKEY J.R., LAI R., DEMETTER P., PEETERS M., POLUS M. et al. Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer, 2010, 116: 5200-5206.
26. KROEP J.R., LOVES W.J., VAN DER WILT C.L., ALVAREZ E., TALIANIDIS I., BOVEN E. et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther., 2002, 1: 371-376.
27. RUIZ VAN HAPEREN V.W.T., VEERMAN G., BOVEN E., STEGMANN A.P., HERMSEN M. et al. Development and characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Res., 1994, 54: 4138-4143.
28. NAKANO Y., TANNO S., KOIZUMI K., NISHIKAWA T., NAKAMURA K., MINOGUCHI M. et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer, 2007, 96: 457-463.
29. COSTANTINO C.L., WITKIEWICZ A.K., KUWANO Y., COZZITORTO J.A., KENNEDY E.P., DASGUPTA A. et al. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res., 2009, 69: 4567-4572.
30. RICHARDS N.G., RITTENHOUSE D.W., FREYDIN B., COZZITORTO J.A., GRENDA D., RUI H. et al. HuR status is a powerful marker for prognosis and response to gemcitabine chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann. Surg., 2010, 252: 499-505.
31. MARECHAL R., VAN LAETHEM J.L. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment. Expert. Rev. Anticancer Ther., 2009, 9: 1439-1441.
32. KELNER G.S., KENNEDY J., BACON K.B., KLEYENSTEUBER S., LARGAESPADA D.A., JENKINS N.A. et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science, 1994, 266: 1395-1399.
33. BAGGIOLINI M., DEWALD B., MOSER B. Human chemokines: an update. Annu. Rev. Immunol., 1997, 15: 675-705.
34. ROLLINS B.J. Chemokines. Blood, 1997, 90: 909-928.
35. NAGASAWA T., KIKUTANI H., KISHIMOTO T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor? Proc. Natl. Acad. Sci. USA, 1994, 91: 2305-2309.
36. BLEUL C.C., FUHLBRIGGE R.C., CASASNOVAS J.M., AIUTI A., SPRINGER T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor1 (SDF-1). J. Exp. Med., 1996, 184: 1101-1109.
37. NAGASAWA T., HIROTA S., TACHIBANA K., TAKAKURA N., NISHIKAWA S., KITAMURA Y. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature, 1996, 382: 635-638.
38. MARECHAL R., DEMETTER P., VAN LAETHEM J.L. Prognostic and predictive factors in resected pancreatic adenocarcinoma. Belg. J. Med. Oncol., 2011, 5: 77-79.
39. WELLS T.N., POWER C.A., LUSTI NARASIMHAN M., HOOGEWERF A.J., COOKE R.M., CHUNG C.W. et al. Selectivity and antagonism of chemokine receptors. J. Leukoc. Biol., 1996, 59: 53-60.
40. KAIFI J.T., YEKEBAS E.F., SCHURR P., OBONYO D., WACHOWIAK R., BUSCH P. et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J. Natl. Cancer Inst., 2005, 97: 1840-1847.
41. KIM J., TAKEUCHI H., LAM S.T., TURNER R.R., WANG H.J., KUO C. et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J. Clin. Oncol., 2005, 23: 2744-2753.
42. SCHIMANSKI CC., SCHWALD S., SIMIANTONAKI N., JAYASINGHE C., GONNER U., WILSBERG V. et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res., 2005, 11: 1743-1750.
43. KOSHIBA T., HOSOTANI R., MIYAMOTO Y., IDA J., TSUJI S., NAKAJIMA S. et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res., 2000, 6: 3530-3535.
44. MARCHESI F., MONTI P., LEONE B.E., ZERBI A., VECCHI A., PIEMONTI L. et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res., 2004, 64: 8420-8427.
45. SAUR D., SEIDLER B., SCHNEIDER G., ALGUL H., BECK R., SENEKOWITSCH-SCHMIDTKE R. et al. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer. Gastroenterology, 2005, 129: 1237-1250.
46. SINGH S., SRIVASTAVA S.K., BHARDWAJ A., OWEN L.B., SINGH A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br. J. Cancer, 2010, 103: 1671-1679.
47. HERMANN P.C., HUBER S.L., HERRLER T., AICHER A., ELLWART J.W., GUBA M. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1: 313-323.
48. BURNS J.M., SUMMERS B.C., WANG Y., MELIKIAN A., BERAHOVICH R., MIAO Z. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med., 2006, 203: 2201-2213.
49. MIAO Z., LUKER K.E., SUMMERS B.C., BERAHOVICH R., BHOJANI M.S., REHEMTULLA A. et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. USA, 2007, 104: 15735-15740.
50. MEIJER J., OGINK J., ROOS E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. Br. J. Cancer, 2008, 99: 1493-1501.
51. MARECHAL R., DEMETTER P., NAGY N., BERTON A., DECAESTECKER C., POLUS M. et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br. J. Cancer, 2009, 100: 1444-1451.
52. BACHET J.B., MARECHAL R., DEMETTER P., BONNETAIN F., COUVELARD A., SVRCEK M. et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann. Oncol., 2012, Feb. 29 (Epub ahead of print).
53. APTE M.V., PARK S., PHILLIPS P.A., SANTUCCI N., GOLDSTEIN D., KUMAR R.K. et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas, 2004, 29: 179-187.
54. BACHEM M.G., SCHUNEMANN M., RAMADANI M., SIECH M., BEGER H., BUCK A. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology, 2005, 128: 907-921.
55. APTE M.V., PHILLIPS P.A., FAHMY R.G., DARBY S.J., RODGERS S.C., MC CAUGHAN G.W. et al. Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. Gastroenterology, 2000, 118: 780-794.
56. CASINI A., GALLI A., PIGNALOSA P., FRULLONI L., GRAPPONE C., MILANI S. et al. Collagen type I synthesized by pancreatic periacinar stellate cells (PSC) co-localizes with lipid peroxidation-derived aldehydes in chronic alcoholic pancreatitis. J. Pathol., 2000, 192: 81-89.
57. APTE M.V., WILSON J.S. Stellate cell activation in alcoholic pancreatitis. Pancreas, 2003, 27: 316-320.
58. WEHR A.Y., FURTH E.E., SANGAR V., BLAIR I.A., YU K.H. Analysis of the human pancreatic stellate cell secreted proteome. Pancreas, 2011, 40: 557-566.
59. VONLAUFEN A., PHILLIPS P.A., XU Z., GOLDSTEIN D., PIROLA R.C., WILSON J.S. et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res., 2008, 68: 7707-7710.
60. DUNER S., LINDMAN J.L., ANSARI D., GUNDEWAR C., ANDERSSON R. Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology, 2010, 10: 673-681.
61. MANTONI T.S., LUNARDI S., AL-ASSAR O., MASAMUNE A., BRUNNER T.B. Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Cancer Res., 2011, 71: 3453-3458.
62. KIKUTA K., MASAMUNE A., WATANABE T., ARIGA H., ITOH H., HAMADA S. et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem. Biophys. Res. Commun., 2010, 403: 380-384.
63. VONLAUFEN A., JOSHI S., QU C., PHILLIPS P.A., XU Z., PARKER N.R. et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res., 2008, 68: 2085-2093.
64. JASTER R., SPARMANN G., EMMRICH J., LIEBE S. Extracellular signal regulated kinases are key mediators of mitogenic signals in rat pancreatic stellate cells. Gut, 2002, 51: 579-584.
65. MASAMUNE A., SUZUKI N., KIKUTA K., SATOH M., SATOH K., SHIMOSEGAWA T. Curcumin blocks activation of pancreatic stellate cells. J. Cell. Biochem., 2006, 97: 1080-1093.
66. HE J., SUN X., QIAN KQ., LIU X., WANG Z., CHEN Y. Protection of cerulein-induced pancreatic fibrosis by pancreas-specific expression of Smad7. Biochim. Biophys. Acta, 2009, 1792: 56-60.